A crisis in clinical research by Mario Sznol, Patricia LoRusso, David S Hong

Get full text

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma by Mario Sznol, Harriet M. Kluger, Pok Fai Wong, James W. Smithy, David L. Rimm, Vasiliki Pelekanou, Lauren M. Moore, Jamaal Rehman, Patricia Gaule, Veronique M. Neumeister

Get full text

Role of high-dose interleukin-2 for melanoma in the age of cellular therapy by Mario Sznol, Elizabeth Buchbinder, Rodabe Amaria, Amod Sarnaik, David F McDermott, Michael B Atkins, Ann W Silk, Kim A Margolin, Michael T Lotze, Zeynep Eroglu, Virginia Seery, Allison Betof Warner, Harriet M Kluger, Karam Khaddour

Get full text

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce by Mario Sznol, Roberta Zappasodi, Margaret K. Callahan, Dung T. Le, Robert L. Ferris, James L. Gulley, Charles G. Drake, Ryan J. Sullivan, Elad Sharon, Hussein A. Tawbi, Harriet M. Kluger, Janis M. Taube, Shilpa Gupta, Suzanne L. Topalian, Edward Cha, Michael A. Postow, Vassiliki A. Papadimitrakopoulou, Maria L. Ascierto, Michaela Bowden, Helen X. Chen, David M. Feltquate, Rachel W. Humphrey, Theresa M. LaVallee, Vanessa M. Hubbard-Lucey, Eric H. Rubin

Get full text